Daidzein analogs as treatment for cancer

US8962679B2 · kind B2 · utility

Assignees

• The Administrators of the Tulane Educational Fund · US
• Xavier University of Louisiana · US

Inventors

• Guangdi Wang · New Orleans, US
• Matthew E. Burow · New Orleans, US
• Stephen M. Boue · New Orleans, US
• Thomas E. Wiese · New Orleans, US
• Quan Jiang · New Orleans, US

Key dates

• Filing date: Jul 8, 2011
• Grant date: Feb 24, 2015
• Expiry date: Jul 8, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D493/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.